Laboratory Investigation of Hypercoagulability
暂无分享,去创建一个
[1] S. Eichinger,et al. Hyperhomocysteinemia Is a Risk Factor of Recurrent Venous Thromboembolism , 1998, Thrombosis and Haemostasis.
[2] E. Svenungsson,et al. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. , 1998, The American journal of medicine.
[3] F R Rosendaal,et al. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. , 1997, Blood.
[4] T. Frebourg,et al. The A20210 allele of the prothrombin gene is not frequently associated with the factor V Arg 506 to Gln mutation in thrombophilic families. , 1997, Blood.
[5] A. Cumming,et al. The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population , 1997, British journal of haematology.
[6] H. McNulty,et al. Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. , 1997, QJM : monthly journal of the Association of Physicians.
[7] A. Duncan,et al. A patient homozygous for a mutation in the prothrombin gene 3'-untranslated region associated with massive thrombosis. , 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[8] P. Mannucci,et al. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. , 1997, Circulation.
[9] P. Harpel. Homocysteine, atherogenesis and thrombosis , 1997 .
[10] T. Meyer,et al. Temporal Changes in the Activated Protein C Resistance Ratio in a Heterozygote for Factor V Leiden Are Abolished by Dilution in Factor V-Deficient Plasma , 1997 .
[11] R. Tait,et al. Isolated Familial Plasminogen Deficiency May not Be a Risk Factor for Thrombosis , 1996, Thrombosis and Haemostasis.
[12] P. Reitsma,et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.
[13] G. Escolar,et al. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein s. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[14] Y. Wilson,et al. Hyperhomocysteinaemia is a risk factor for vein graft stenosis. , 1996, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[15] B. Lämmle,et al. Plasminogen Deficiency: An Additional Risk Factor for Thrombosis in a Family with Factor V R506Q Mutation? , 1996, Thrombosis and Haemostasis.
[16] Y. Wilson,et al. Homocysteine: An independent risk factor for the failure of vascular intervention , 1996, The British journal of surgery.
[17] D. Triplett,et al. APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method. , 1996, Thrombosis research.
[18] H. Hemker,et al. A Prothrombinase-based Assay for Detection of Resistance to Activated Protein C , 1996, Thrombosis and Haemostasis.
[19] M. Levene,et al. Determination of plasma total homocysteine and cysteine using HPLC with fluorescence detection and an ammonium 7-fluoro-2, 1, 3-benzoxadiazole-4-sulphonate (SBD-F) derivatization protocol optimized for antioxidant concentration, derivatization reagent concentration, temperature and matrix pH. , 1996, Biomedical chromatography : BMC.
[20] B. Chadefaux-Vekemans,et al. Thrombophilia, homocystinuria, and mutation of the factor V gene. , 1996, The New England journal of medicine.
[21] K. Voelkerding,et al. Factor V R506Q gene mutation analysis by PCR-RFLP: optimization, comparison with functional testing for resistance to activated protein C, and establishment of cell line controls. , 1996, American journal of clinical pathology.
[22] B. Evatt,et al. Oligonucleotide ligation assay for detection of the factor V mutation (Arg506-->Gln) causing protein C resistance. , 1996, Thrombosis research.
[23] A. Michelson. Flow cytometry: a clinical test of platelet function. , 1996, Blood.
[24] J. Jespersen,et al. Influence of blood handling on determination of plasma resistance against activated protein C , 1996 .
[25] J. Montoro,et al. A modification of the APC resistance test and its application to the study of patients on coumarin therapy. , 1996, Thrombosis research.
[26] A. Tosetto,et al. Thrombosis in Patients with Heterozygous and Homozygous Factor XII Deficiency Is not Explained by the Associated Presence of Factor V Leiden , 1996, Thrombosis and Haemostasis.
[27] P. Reitsma,et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. , 1996, The New England journal of medicine.
[28] L. Kuritzky. Homocysteine as a risk factor for arteriosclerosis. , 1996, Hospital Practice.
[29] J. Lindemans,et al. Phenotyping and Genotyping of Coagulation Factor V Leiden , 1996, Thrombosis and Haemostasis.
[30] J. Vandenbroucke,et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen , 1995, The Lancet.
[31] J. Brandt,et al. Laboratory Identification of Lupus Anticoagulants: Results of the Second International Workshop for Identification of Lupus Anticoagulants , 1995, Thrombosis and Haemostasis.
[32] J. Fontcuberta,et al. Low levels of tissue factor pathway inhibitor (TFPI) in two out of three members of a family with thrombophilia. , 1995, Thrombosis research.
[33] J. Griffin,et al. Alternative PCR method for diagnosis of mutation causing activated protein C resistant Gln506-factor V. , 1995, Thrombosis research.
[34] J. Laissy,et al. Fatal Cerebral Venous Sinus Thrombosis Associated with the Factor V Leiden Mutation and the Use of Oral Contraceptives , 1995, Thrombosis and Haemostasis.
[35] E. Mensink,et al. Semi-Automated Detection of the Factor V Mutation by Allele Specific Amplification and Capillary Electrophoresis , 1995, Thrombosis and Haemostasis.
[36] I. Scharrer,et al. Criteria for the Diagnosis of Lupus Anticoagulants: An Update , 1995, Thrombosis and Haemostasis.
[37] J. Gil,et al. False Positive Activated Protein C Resistance Test due to Anti-Phospholipid Antibodies Is Corrected by Platelet Extract , 1995, Thrombosis and Haemostasis.
[38] P. Reitsma,et al. Factor V Leiden: An Additional Risk Factor for Thrombosis in Protein S Deficient Families? , 1995, Thrombosis and Haemostasis.
[39] D. W. Jones,et al. Should factor XII assays be included in thrombophilia screening? , 1995, The Lancet.
[40] M. Shipchandler,et al. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMx analyzer. , 1995, Clinical chemistry.
[41] C. Traverso,et al. Thromboelastography for the Assessment of Hypercoagulability During General Surgery , 1995, Seminars in Thrombosis & Hemostasis.
[42] H. Blom,et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? , 1995, The Lancet.
[43] J. Griffin,et al. Use of a generally applicable tissue factor--dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. , 1995, Blood.
[44] B. Dahlbäck. Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism , 1995, Journal of internal medicine.
[45] P. Moerloose,et al. Multicenter Evaluation of Nine Commercial Kits for the Quantitation of Anticardiolipin Antibodies , 1995, Thrombosis and Haemostasis.
[46] S. Testa,et al. Variable interference of activated protein C resistance in the measurement of protein S activity by commercial assays. , 1995, Thrombosis research.
[47] M. Wygoda,et al. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin. , 1995, Israel journal of medical sciences.
[48] E. Mammen. Ten Years' Experience with the "Sticky Platelet Syndrome" , 1995 .
[49] P. Mannucci,et al. Another Protein S Functional Assay Is Sensitive to Resistance to Activated Protein C , 1994, Thrombosis and Haemostasis.
[50] B. Dahlbäck. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. , 1994, The Journal of clinical investigation.
[51] M. Makris,et al. Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency , 1994, British journal of haematology.
[52] P. Reitsma,et al. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. , 1994, Blood.
[53] Y. Shoenfeld,et al. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. , 1994, Journal of immunology.
[54] J. Vandenbroucke,et al. John Hageman's factor and deep‐vein thrombosis: Leiden Thrombophilia Study , 1994, British journal of haematology.
[55] J. Francis,et al. Assessment of hypercoagulability in patients with cancer using the Sonoclot Analyzer and thromboelastography. , 1994, Thrombosis research.
[56] Pieter H. Reitsma,et al. Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.
[57] B. Dahlbäck,et al. Resistance to activated protein C as a basis for venous thrombosis. , 1994, The New England journal of medicine.
[58] W. Halbmayer,et al. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[59] Y. Shoenfeld,et al. Antiphospholipid Antibodies: A Critique of Their Heterogeneity and Hegemony , 1994, Seminars in thrombosis and hemostasis.
[60] E. Sacchi,et al. Resistance to Activated Protein C in Nine Thrombophilic Families: Interference in a Protein S Functional Assay , 1993, Thrombosis and Haemostasis.
[61] F. Rosendaal,et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study , 1993, The Lancet.
[62] H. Philippou,et al. Thrombogenic mechanisms in the human: fresh insights obtained by immunodiagnostic studies of coagulation markers. , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[63] J. Griffin,et al. Anticoagulant protein C pathway defective in majority of thrombophilic patients. , 1993, Blood.
[64] B. Hinney,et al. Factor XII (Hageman) deficiency in women with habitual abortion: New subpopulation of recurrent aborters? , 1993, Fertility and sterility.
[65] G. Broze,et al. The Role of Factor XI in Coagulation , 1993, Thrombosis and Haemostasis.
[66] R. Colman,et al. Tissue factor is expressed on monocytes during simulated extracorporeal circulation. , 1993, Circulation research.
[67] B. Dahlbäck,et al. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[68] S. Thein,et al. Antithrombin and its deficiency states. , 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[69] R. Rivers,et al. The Expression of Surface Tissue Factor Apoprotein by Blood Monocytes in the Course of Infections in Early Infancy , 1992, Pediatric Research.
[70] P. Fay,et al. Regulation of blood coagulation by the protein C system , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[71] T. Shigekiyo,et al. Type I Congenital Plasminogen Deficiency Is not a Risk Factor for Thrombosis , 1992, Thrombosis and Haemostasis.
[72] C. Esmon. The protein C anticoagulant pathway. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.
[73] D. Perry,et al. Antithrombin III: A Database of Mutations , 1991, Thrombosis and Haemostasis.
[74] R. Hoffmann. The thrombo-embolic risk in surgery. , 1991, Hepato-Gastroenterology.
[75] D. Rader,et al. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. , 1991, Blood.
[76] A. Gori,et al. Monocyte activation and increased procoagulant activity in unstable angina , 1990, The Lancet.
[77] H. Büller,et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. , 1990, The New England journal of medicine.
[78] J. Moreb,et al. Acquired functional protein S deficiency, cerebral venous thrombosis, and coumarin skin necrosis in association with antiphospholipid syndrome: report of two cases. , 1989, The American journal of medicine.
[79] P. Callas,et al. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. , 1989, Blood.
[80] J. Marrinan,et al. Antithrombin III Utah: proline-407 to leucine mutation in a highly conserved region near the inhibitor reactive site. , 1988, Biochemistry.
[81] P. White,et al. Time dependency of lupuslike anticoagulants. , 1988, Archives of internal medicine.
[82] J. Miletich,et al. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action , 1988 .
[83] S. Carson,et al. Continuous chromogenic tissue factor assay: comparison to clot-based assays and sensitivity established using pure tissue factor. , 1987, Thrombosis research.
[84] E. Briët,et al. Hereditary protein S deficiency: clinical manifestations. , 1987, Annals of internal medicine.
[85] R. Bertina,et al. Hereditary Heparin Cofactor II Deficiency and the Risk of Development of Thrombosis , 1987, Thrombosis and Haemostasis.
[86] F. Rickles,et al. Activation of blood coagulation in Crohn's disease. Increased plasma fibrinopeptide A levels and enhanced generation of monocyte tissue factor activity. , 1987, Gastroenterology.
[87] C. Esmon,et al. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. , 1986, Blood.
[88] D. Feinstein. Lupus anticoagulant, thrombosis, and fetal loss. , 1985, The New England journal of medicine.
[89] J H Lewis,et al. Intraoperative Changes in Blood Coagulation and Thrombelastographic Monitoring in Liver Transplantation , 1985, Anesthesia and analgesia.
[90] B. Boneu,et al. CONSTITUTIONAL HEPARIN CO-FACTOR II DEFICIENCY ASSOCIATED WITH RECURRENT THROMBOSIS , 1985, The Lancet.
[91] G. Marbet,et al. ASSOCIATION OF HEREDITARY HEPARIN CO-FACTOR II DEFICIENCY WITH THROMBOSIS , 1985, The Lancet.
[92] C. Esmon,et al. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. , 1984, The New England journal of medicine.
[93] J. Griffin,et al. Plasma protein S deficiency in familial thrombotic disease. , 1984, Blood.
[94] N. Palasciano,et al. Increased production of procoagulant activity (tissue factor) by human peripheral blood monocytes after Intralipid infusion. , 1984, Clinical nutrition.
[95] F. Rickles,et al. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. , 1981, The Journal of laboratory and clinical medicine.
[96] J. Griffin,et al. Deficiency of protein C in congenital thrombotic disease. , 1981, The Journal of clinical investigation.
[97] D. Tollefsen,et al. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. , 1981, The Journal of clinical investigation.
[98] S. D. Peck. Evaluation of the In Vitro Detection of the Hypercoagulable State Using the Thrombin Generation Test and Plasma Clot Impedance Test , 1979, Thrombosis and Haemostasis.
[99] A. Ur. ANTITHROMBIN III AND HEPARIN , 1978, The Lancet.
[100] W. Droegemueller,et al. Conjugated estrogens and hypercoagulability. , 1975, American journal of obstetrics and gynecology.
[101] O. Egeberg. Inherited Antithrombin Deficiency Causing Thrombophilia , 1965, Thrombosis and Haemostasis.
[102] C. Schneider. The active principle of placental toxin; thromboplastin; its inactivator in blood; antithromboplastin. , 1947, The American journal of physiology.
[103] P. Frosst,et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. , 1996, American journal of human genetics.
[104] G. Warnes,et al. The Importance of Platelets in the Expression of Monocyte Tissue Factor Antigen Measured by a New Whole Blood Flow Cytometric Assay , 1996, Thrombosis and Haemostasis.
[105] B. Dahlbäck. Dr. Dahlbäck’s Response to the Letter by Dr. Keeling - Factor V: Q506 and a Negative APC-Resistance Test - Modified APC-Resistance Test Offers Increased Sensitivity and Specificity for the FV: Q506 Allele , 1995, Thrombosis and Haemostasis.
[106] R J Jarvis,et al. A mathematical analysis of a model for tumour angiogenesis , 1995, Journal of mathematical biology.
[107] K. Preissner,et al. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. , 1995, The Journal of laboratory and clinical medicine.
[108] C. Mannhalter,et al. The Prevalence of Moderate and Severe FXII (Hageman Factor) Deficiency among the Normal Population: Evaluation of the Incidence of FXII Deficiency among 300 Healthy Blood Donors , 1994, Thrombosis and Haemostasis.
[109] K. Bauer. Laboratory markers of coagulation activation. , 1993, Archives of pathology & laboratory medicine.
[110] K. Sakariassen,et al. Mechanisms of thromboembolism at arterial plaques. , 1993, Blood Coagulation and Fibrinolysis.
[111] C. Mannhalter,et al. [Factor XII (Hageman factor) deficiency: a risk factor for development of thromboembolism. Incidence of factor XII deficiency in patients after recurrent venous or arterial thromboembolism and myocardial infarction]. , 1993, Wiener medizinische Wochenschrift.
[112] S. Chollet-Martin,et al. Increased monocyte procoagulant activity in patients with systemic lupus erythematosus. , 1990, Nouvelle revue francaise d'hematologie.
[113] D. Stern,et al. Regulation of the coagulation system by vascular endothelial cells. , 1988, Haemostasis.
[114] H. Hemker,et al. Measurement of macrophage cellular procoagulant activity. , 1985, Haemostasis.
[115] S. Roath,et al. Normal Blood Coagulation, Fibrinolysis, and Natural Inhibitors of Coagulation , 1985, International Anesthesiology Clinics.
[116] U. Abildgaard,et al. On the clinical significance of acquired antithrombin deficiency. , 1984, Folia haematologica.
[117] R. C. Franz,et al. The thrombelastographic diagnosis of hemostatic defects. , 1981, Surgery annual.
[118] U. Abildgaard,et al. Antithrombin III: Critical Review of Assay Methods. Significance of Variations in Health and Disease , 1977, Thrombosis and Haemostasis.
[119] K. V. von Kaulla,et al. The impedance machine: a new bedside coagulation recording device. , 1975, Journal of medicine.